Cytokinetics' Myqorzo: The Challenger Drug Poised to Reshape a Multi-Billion Dollar Heart Market

Related Articles

What Makes Cytokinetics' MYQORZO Launch a Game Changer

8 months ago

Is the FDA Poised to Reshape the Peptide Market

7 months ago

Why is Laurus Investment Counsel Making a Multi-Billion Dollar Bet on Microsoft

7 months ago

AMD's Anthropic Bet: A Multi-Billion-Dollar Validation with a Valuation Catch

3 months ago

Category

You may also like

Stock News•2 weeks ago

Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product

Braveheart Bio holds $527M in pro forma cash, funding two Phase 3 HCM programs into 2029, including LIONHEART-HCM and NOBLEHEART-HCM. Phase 2 data show rapid, reversible effects with minimal LVEF decl...

HCM

Share

Stock News•1 months ago

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos received a broader FDA label and posted strong sales growth, but emerging competitors and pipeline setbacks cloud its cardiovascular outlook.

BMY

Share

Stock News•2 months ago

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics' aficamten significantly improved symptoms and exercise capacity in late-stage data for patients with a genetic heart condition lacking approved treatments, potentially expanding the drug...

CYTK

Share